^
Association details:
| Biomarker: | EGFR mutation + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer
Published date:
04/18/2022
Excerpt:
A total of 54 patients from our hospital with non-small cell lung cancer harboring EGFR-sensitive mutations and/or de novo MET amplifications were included in this study….Survival rates for EGFR+/METamp- and EGFR+/METamp + patients respectively, were as follows: the median progression-free survival (PFS) was 12.1 and 1.9 months (p<0.001); the median post-progression overall survival (pOS) was 25.6 and 11.6 months (p = 0.023); the median overall survival (OS) was 33.2 and 12.7 months (p = 0.013)....EGFR+/METamp + patients treated with first-line TKI monotherapy had poor clinical outcomes.
DOI:
10.1111/1759-7714.14429
Source:
Title:
Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Published date:
06/21/2021
Excerpt:
We retrospectively analyzed 186 patients with advanced EGFR-mutant NSCLC for MET amplification...The median PFS for the most recent EGFR-TKI treatment was shorter in MET amplification-positive patients than in MET amplification-negative patients (median PFS 7.0 vs. 10.4 months, p = 0.004).
DOI:
10.3390/cancers13123096
Source:
Title:
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Published date:
06/16/2021
Excerpt:
...de novo MET/ERBB2 amplification in patients harboring EGFR-mutant NSCLC treated with first-generation EGFR tyrosine kinase inhibitors (TKIs) was associated with shorter PFS (p < 0.05).
DOI:
10.3389/fonc.2021.665484
